ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcome Predictors with Perioperative Kidney Transplant Midodrine Usage

R. Watson1, S. Mullins2, S. Williams3, F. Fakhre4, K. Robichaux4, S. Mohammed4, M. Gosselin3, A. Kumar5, J. Buggs1, V. Bowers1

1Transplant Surgery, Tampa General Hospital, Tampa, FL, 2Florida A &M University, Tallahassee, FL, 3University of Tampa, Tampa, FL, 4University of South Florida, Tampa, FL, 5Morsani College of Medicine, University of South Florida, Tampa, FL

Meeting: 2022 American Transplant Congress

Abstract number: 224

Keywords: Adverse effects, Kidney transplantation

Topic: Clinical Science » Kidney » 35 - Kidney: Cardiovascular and Metabolic Complications

Session Information

Session Name: Kidney: Cardiovascular and Metabolic Complications II

Session Type: Rapid Fire Oral Abstract

Date: Monday, June 6, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 4:50pm-5:00pm

Location: Hynes Veterans Auditorium

*Purpose: Midodrine is an alpha-1 agonist drug commonly used to aid hypotension in kidney transplant patients. Little is described regarding outcomes with midodrine in kidney transplant patients. The purpose of this study was to determine any difference in outcomes for kidney transplant patients on midodrine. We also evaluated outcomes based on the timing of midodrine administration i.e., pre-transplant (Pre-TX), interdialytically (Inter-dial,) or post-transplant (Post-TX).

*Methods: We conducted a retrospective cohort study of consecutive adult (age 18 or older) kidney transplant recipients at a single center from January 2015 to December 2020.

*Results: Of the 1,702 adult patients transplanted during the study period, 210 received midodrine. The two groups were similar in years of age (midodrine 53 vs 52 no midodrine p=0.493) and race (69% or 145 of 210 were White and received midodrine vs 73% or 1082/1492 were White and did not receive midodrine, p=0.141). There was overlap with the timing of midodrine administration with 84 Pre-TX, 53 Inter-dial, and 127 Post-TX. For all midodrine dosing times, the one-month discharge systolic blood pressure (mmHg) remained lower (PRE-TX 124 vs 140, p<0.001, Inter-dial 128 vs 140, p<0.001, and POST-TX 128 vs 140, p<0.001).The six-month diastolic blood pressure remained lower for all midodrine doses (PRE-TX 73 vs 76, p=0.009, Inter-dial 71 vs 76, p=0.001 and POST-TX 73 vs 76, p=0.001). The mean length of stay (days) was longer for all midodrine dosing times (PRE-TX 12 vs 7, p=0.003, Inter-dial 11 vs 7, p=0.118 and POST-TX 11 vs 7, p=0.001). Graft survival days (1684 vs 2068, p<0.001) and patient survival days (1793 vs 2080, p<0.001) were statistically less with midodrine. There was no difference in graft survival (p=.359) or patient survival (p=.539) when comparing the three dosing times for midodrine.

*Conclusions: In conclusion, the use of midodrine in dialysis patients receiving kidney transplantation is a marker for decreased blood pressure, a longer length of stay, and worse graft and patient survival. There was no difference in graft or patient survival based on the timing of the midodrine administration. This information should be considered in the listing and management of transplant patients.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Watson R, Mullins S, Williams S, Fakhre F, Robichaux K, Mohammed S, Gosselin M, Kumar A, Buggs J, Bowers V. Outcome Predictors with Perioperative Kidney Transplant Midodrine Usage [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcome-predictors-with-perioperative-kidney-transplant-midodrine-usage/. Accessed June 7, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences